Regulators

MS Has Learnt to Stop Inflammation. It Still Cannot Repair the Damage.

When diabetes tech fails, personalised care fails with it

AI genomics market set to hit $9.3B by 2030, but regulation and equity gaps remain unresolved

Japan Approves MRD Testing. Price Will Decide Whether Patients Can Use It.

For Drug-Resistant Epilepsy, Surgery Should Not Be the Only Door

A Licensing Deal Is Not Access. But It Decides Whether Access Is Possible.

Gene therapy is entering cardiology. Friedreich ataxia shows why rare heart disease may be the first test

Triglycerides are back in the spotlight. Europe is reviewing Sobi’s olezarsen for severe risk.

A Rare Childhood Ataxia Gets Real Phase III Evidence
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
